Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports

Search

Descriptive Alt Text

Filters

Showing results 2,785–2,792 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
Mineralys Therapeutics Inc. Lorundrostat Chronic Kidney Disease Phase 2 Ongoing Oral N/A
Mineralys Therapeutics Inc. Lorundrostat - (ADVANCE-HTN) Uncontrolled hypertension (uHTN) and resistant hypertension (rHTN) Phase 2 Data Released oral Cardiology
Mineralys Therapeutics Inc. Lorundrostat - (Target-HTN) Hypertension Phase 2 Data Released Oral Cardiology
Minerva Neurosciences Inc Seltorexant - (MIN-202) Primary insomnia Phase 2b Trial Completed Oral Psychiatric
Minerva Neurosciences Inc MIN-117 Major Depressive Disorder Phase 2b Trial Discontinued Oral Psychiatric
Minerva Neurosciences Inc Seltorexant (MIN-202) Major Depressive Disorder Phase 2 Trial Completed Oral Psychiatric
MiNK Therapeutics Inc. AgenT-797 Refractory (2L+) gastric cancer, refractory gastroesophageal cancer (GEC) Phase 2 Data Released Intravenous Oncology
MiNK Therapeutics Inc. Botensilimab plus balstilimab, agenT-797 Gastric cancer Phase 2 Enrollment Initiation Intravenous Oncology